Get the Stockscreener App
2.93
3.62%
-0.11
After Hours:
2.94
0.010
+0.34%
Cytomx Therapeutics Inc stock is traded at $2.93, with a volume of 10.57M.
It is down -3.62% in the last 24 hours and down -18.84% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$3.04
Open:
$3.03
24h Volume:
10.57M
Relative Volume:
1.58
Market Cap:
$637.87M
Revenue:
$35.54M
Net Income/Loss:
$-59.14M
P/E Ratio:
-8.0561
EPS:
-0.3637
Net Cash Flow:
$-80.19M
1W Performance:
-1.68%
1M Performance:
-18.84%
6M Performance:
-31.06%
1Y Performance:
+19.11%
1-Day Range:
$2.865
$3.05
1-Week Range:
$2.865
$3.13
52-Week Range:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.93 | 661.82M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments - Yahoo Finance
Transcript : CytomX Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09 - marketscreener.com
CytomX Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
CytomX Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as Pipeline AdvancesAdjusted Earnings Analysis - newsline.com
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX gains as licensing deal with Regeneron expands - MSN
Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing - TradingView
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
CytomX expands Regeneron collaboration, receives $37M payment - Investing.com UK
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron - TipRanks
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
CytomX (NASDAQ: CTMX) adds programs, gains $37M from Regeneron - Stock Titan
CytomX Therapeutics (CTMX) Expands Collaboration with Regeneron Pharmaceuticals - GuruFocus
Why is CytomX Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Why is CytomX Therapeutics stock gaining today? - Investing.com
CytomX stock jumps on $37M Regeneron collaboration payment By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
CytomX expands Regeneron collaboration, receives $37M payment By Investing.com - Investing.com South Africa
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - The Manila Times
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
CytomX (CTMX) Q4 2025 Earnings Transcript - AOL.com
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks - Yahoo Finance
CytomX Therapeutics (CTMX) Holds Steady Near Resistance After 3.25% GainWyckoff Distribution - newsline.com
CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics (CTMX) Holds Steady Near Support – Key Levels to WatchMACD Signal Stocks - The Legal Advocate
Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform - Insider Monkey
CytomX Therapeutics (CTMX) Holds Steady at $3.76 as Consolidation ContinuesRisk Reversal - newsline.com
CytomX Therapeutics to Present at Upcoming June Investor Conferences - The Manila Times
CytomX Therapeutics in June investor events at Jefferies, Goldman Sachs - Stock Titan
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Wolfe Research initiates CytomX stock with outperform rating By Investing.com - Investing.com Australia
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating - Moomoo
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):